Proteolysis targeting chimeras (PROTACs) in cancer therapy

Exploitation of the protein degradation machinery as a therapeutic strategy to degrade oncogenic proteins is experiencing revolutionary advances with the development of proteolysis targeting chimeras (PROTACs). PROTACs are heterobifunctional structures consisting of a ligand that binds a protein to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ocaña, Alberto, Pandiella, Atanasio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493969/
https://www.ncbi.nlm.nih.gov/pubmed/32933565
http://dx.doi.org/10.1186/s13046-020-01672-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493969/
https://www.ncbi.nlm.nih.gov/pubmed/32933565
http://dx.doi.org/10.1186/s13046-020-01672-1

Ejemplares similares